<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cohen, David J.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TAVI Improves QoL in Patients Suitable for Transfemoral TAVI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4-4</style></pages><abstract><style  face="normal" font="default" size="100%">In PARTNER [NCT00530894; Leon MB et al. N Engl J Med 2010] Cohort A, transcatheter aortic valve implantation (TAVI) was shown to be noninferior to surgical aortic valve replacement (SAVR) for 1-year mortality in patients who were at high surgical risk. There were differences in procedure-related complications and valve performance at 1 year, with some endpoints favoring TAVI and others favoring SAVR. These alternative treatments have an impact on health-related quality of life from the perspective of the patient.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>